First-in-human phase 1 study of RO7119929, an oral TLR7 agonist prodrug, in patients with advanced primary or metastatic liver cancers.

In contrast, we did not observe a clear trend for the modulation of M2-like, immune-suppressive gene expression on treatment.

also in 19,460 other papers

Individual M2-like genes such as MRC2 15 showed a trend for decreased expression after RO7119929 treatment, while others, such as TREM2, 16 did not change consistently across patients, or even showed a slight overall increase on treatment, as exemplified by CD163, which may describe a subpopulation of M2-like TAMs 17 ( figure 5C , right).

also in 53,322 other papers